Ionis Pharmaceuticals Reports Olezarsen Cuts Triglycerides and Acute Pancreatitis in sHTG Phase 3 Trial
Reuters
Nov 10, 2025
Ionis Pharmaceuticals Reports Olezarsen Cuts Triglycerides and Acute Pancreatitis in sHTG Phase 3 Trial
Ionis Pharmaceuticals Inc. announced positive results from its pivotal Phase 3 CORE and CORE2 studies evaluating olezarsen for the treatment of severe hypertriglyceridemia (sHTG). The studies met their primary endpoint, demonstrating a placebo-adjusted mean reduction in fasting triglyceride levels of up to 72% at six months, with reductions sustained through 12 months. Olezarsen also achieved an 85% reduction in acute pancreatitis events and enabled 86% of treated patients to reach triglyceride levels below 500 mg/dL, which is below the risk threshold for acute pancreatitis. The drug showed a favorable safety and tolerability profile, as well as significant improvements in secondary lipid endpoints. These results were presented during a late-breaking session at the American Heart Association (AHA) Scientific Sessions and were published in The New England Journal of Medicine.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ionis Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001140361-25-041225), on November 10, 2025, and is solely responsible for the information contained therein.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.